H
Hongwei Ouyang
Researcher at Zhejiang University
Publications - 237
Citations - 13782
Hongwei Ouyang is an academic researcher from Zhejiang University. The author has contributed to research in topics: Regeneration (biology) & Mesenchymal stem cell. The author has an hindex of 59, co-authored 223 publications receiving 10618 citations. Previous affiliations of Hongwei Ouyang include Sir Run Run Shaw Hospital & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Electrospinning of gelatin fibers and gelatin/PCL composite fibrous scaffolds.
TL;DR: The results suggest the potential of using composite gelatin/PCL fibrous scaffolds for engineering three-dimensional tissues as a promising scaffold for bone-marrow stromal cell culture.
Journal ArticleDOI
The regulation of tendon stem cell differentiation by the alignment of nanofibers.
TL;DR: The aligned electrospun nanofiber structure provides an instructive microenvironment for hTSPC differentiation and may lead to the development of desirable engineered tendons.
Journal ArticleDOI
A strongly adhesive hemostatic hydrogel for the repair of arterial and heart bleeds
Yi Hong,Zhou Feifei,Hua Yujie,Xianzhu Zhang,Chengyao Ni,Dihao Pan,Zhang Yiqing,Deming Jiang,Long Yang,Qiuning Lin,Yiwei Zou,Dongsheng Yu,David E. Arnot,Xiaohui Zou,Linyong Zhu,Shufang Zhang,Hongwei Ouyang +16 more
TL;DR: A photo-reactive adhesive that mimics the composition of connective tissue and is able to stop high pressure bleeding within half a minute is designed, which appears to offer significant clinical advantage as a traumatic wound sealant.
Journal ArticleDOI
Knitted poly-lactide-co-glycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of rabbit Achilles tendon.
TL;DR: The results suggest that the knitted PLGA biodegradable scaffold loaded with allogeneic bone marrow stromal cells has the potential to regenerate and repair gap defect of Achilles tendon and to effectively restore structure and function.
Journal ArticleDOI
Current research on pharmacologic and regenerative therapies for osteoarthritis.
TL;DR: Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against β-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones.